Group 1 - The medical beauty sector experienced a decline of 0.14% on October 29, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 4016.33, up 0.7%, while the Shenzhen Component Index closed at 13691.38, up 1.95% [1] - Key stocks in the medical beauty sector showed varied performance, with Jinbo Biological rising by 7.46% and Ai Meike falling by 1.97% [1] Group 2 - The medical beauty sector saw a net outflow of 23.498 million yuan from main funds, while retail investors had a net inflow of 39.3117 million yuan [1] - Specific stock fund flows indicated that Huaxi Biological had a main fund inflow of 8.119 million yuan, while Ai Meike experienced a significant outflow of 29.5668 million yuan [2] - The overall trend showed that retail investors were more active in the sector, with a net inflow across several stocks despite the main and speculative funds pulling back [2]

Core Viewpoint - Jinbo Biological (920982) experienced a block trade on October 28, with a transaction volume of 10,800 shares and a transaction amount of 2.2324 million yuan, at a price of 206.00 yuan, which represents a discount of 16.21% compared to the closing price of the day [2] Group 1: Block Trade Details - The block trade involved a total volume of 10,800 shares and a total transaction amount of 2.2324 million yuan [2] - The transaction price was 206.00 yuan, reflecting a discount of 16.21% relative to the closing price of the day [2] - The buyer was from Guojin Securities Co., Ltd. Shanghai Jing'an District Nanjing West Road Securities Business Department, while the seller was from Guojin Securities Co., Ltd. Shenzhen Branch [2] Group 2: Recent Trading Activity - In the past month, Jinbo Biological has recorded a total of 3 block trades, with a cumulative transaction amount of 7.2333 million yuan [2] - The closing price of Jinbo Biological on the day of the block trade was 245.86 yuan, which represents a decline of 2.05%, with a turnover rate of 2.21% and a total transaction amount of 299 million yuan [2] - Over the last 5 days, the stock has seen a cumulative decline of 6.83% [2] Group 3: Company Background - Shanxi Jinbo Biological Pharmaceutical Co., Ltd. was established on March 28, 2008, with a registered capital of 1,150.6534 million yuan [2]

Core Viewpoint - The medical beauty sector experienced a decline of 1.44% on October 28, with Jinbo Biological leading the drop. The Shanghai Composite Index closed at 3988.22, down 0.22%, while the Shenzhen Component Index closed at 13430.1, down 0.44% [1]. Group 1: Market Performance - The medical beauty sector's individual stock performance showed the following results: - Huaxi Biological closed at 52.72, down 1.03% with a trading volume of 18,000 shares and a transaction value of 95.6261 million yuan [1]. - *ST Meigu closed at 3.56, down 1.39% with a trading volume of 130,900 shares and a transaction value of 47.2460 million yuan [1]. - Aimeike closed at 163.54, down 1.74% with a trading volume of 32,100 shares and a transaction value of 529 million yuan [1]. - Jinbo Biological closed at 245.86, down 2.05% with a trading volume of 12,100 shares and a transaction value of 299 million yuan [1]. Group 2: Capital Flow - On the same day, the medical beauty sector saw a net outflow of 35.3969 million yuan from main funds, a net outflow of 24.4121 million yuan from speculative funds, and a net inflow of 59.809 million yuan from retail investors [2].

Core Insights - A block trade of 15,900 shares of Jinbo Biological (920982) occurred on October 27, with a transaction value of 3.9909 million yuan at a price of 251.00 yuan per share [1] - The buyer was Huatai Securities Co., Ltd. Kunshan Heilongjiang North Road Securities Business Department, and the seller was Guojin Securities Co., Ltd. Shenzhen Branch [1] Trading Activity - In the past month, Jinbo Biological has recorded a total of 2 block trades, amounting to a cumulative transaction value of 5.0009 million yuan [1] - The closing price of Jinbo Biological on the day of the block trade was 251.00 yuan, reflecting a decrease of 2.15%, with a daily turnover rate of 2.12% and a total trading volume of 293 million yuan [1] - Over the last five days, the stock has seen a cumulative decline of 3.83% [1] Company Background - Shanxi Jinbo Biological Pharmaceutical Co., Ltd. was established on March 28, 2008, with a registered capital of 1,150.6534 million yuan [1]

Core Insights - The recombinant collagen injection material market is seeing new entrants, with Juzi Bio (2367.HK) receiving approval for its recombinant type I collagen product for facial dermal filling, potentially disrupting the dominance of Jinbo Bio (920982.BJ) [1][2] Company Developments - Juzi Bio's product is composed of recombinant type I collagen, specifically a sequence of 753 amino acids, which does not have a triple helix structure, and is aimed at correcting dynamic facial wrinkles [1][2] - Jinbo Bio previously held a monopoly in the recombinant collagen injection market, with projected revenues of 1.443 billion yuan for 2024, reflecting over 80% year-on-year growth [2] Market Dynamics - The materials used by Juzi Bio and Jinbo Bio differ, with Juzi's focusing on type I collagen for structural support, while Jinbo's core material is type III collagen, which is responsible for elasticity [3] - Both companies have received approval for similar indications related to facial dermal filling, indicating that competition in the market is likely to intensify as more products gain regulatory approval [3]

Core Insights - The collagen market is experiencing significant growth driven by increasing consumer focus on efficacy and ingredients, with two main growth drivers: professional skin care and aesthetic injection applications [1][3] - The collagen market in China is projected to exceed 16 billion yuan at the raw material level and approach 270 billion yuan at the retail level by 2030 [1] - The industry is currently in a phase of policy refinement, accelerated technological iteration, and tight collaboration across the supply chain [1] Industry Structure - The collagen industry has a high degree of integration between raw material supply and end product manufacturing, with upstream suppliers, midstream manufacturers of recombinant collagen, and downstream sales channels [2] - The market is characterized by significant growth potential, high technological barriers, and intense competition [2] End-User Applications - The demand for professional skin care products that combine medical safety and cosmetic efficacy is rapidly increasing, particularly in the aesthetic medicine sector [3] - Applications of collagen products are expanding from traditional moisturizing and nourishing functions to include core roles in aesthetic injection materials [3] Recommended Companies - Companies to watch include: Giant Bio (02367), Jinbo Bio (920982.BJ), Marubi Bio (603983.SH), Huaxi Bio (688363.SH), Fulejia (301371.SZ), Novozymes (688105.SH), Baipusais (301080.SZ), and Betaini (300957.SZ) [4]

Group 1 - The medical beauty sector experienced a decline of 0.12% on October 23, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] - Key stocks in the medical beauty sector showed mixed performance, with Aimeike rising by 0.64% and Jinbo Biological falling by 2.84% [1] Group 2 - The net outflow of main funds in the medical beauty sector was 32.09 million yuan, while retail funds saw a net inflow of 10.22 million yuan [1] - Specific stock fund flows indicated that *ST Meigu experienced a main fund outflow of 6.29 million yuan, while retail funds had a net inflow of 6.18 million yuan [2] - Huaxi Biological also faced a main fund outflow of 10.03 million yuan, with retail funds showing a net inflow of 4.67 million yuan [2]

关于股东所持公司股票自愿限售的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、 本次股票自愿限售数量共计 5,753,267 股，占公司总股本 5%，涉及自愿限售股 东 1 名。 二、 本次股票自愿限售的明细情况 单位：股 | | | 是否为控股 | | 截止2025年10 | | 本次自愿限售 | 本次自愿 | 本次限售股 | | 本次限售后 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 序号 | 股东姓名或名 | 股东、实际 | 任职情况 | 月 10 | 日持股数 | 前已处于限售 | 限售登记 | 数占公司总 | 自愿限售期 | 该股东所持 | | | 称 | 控制人或其 | | | | 登记状态的股 | | | 间 | 的无限售条 | | | | 一致行动人 | | | 量 | 票 | 股票数量 | 股本比例 | | 件股份数量 | | 1 | 久视管理咨询 | 否 | 否 | | 5,7 ...

Group 1 - The medical beauty sector experienced a decline of 0.94% on October 20, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] - Major stocks in the medical beauty sector showed mixed performance, with *ST Meigu closing at 3.51, up 1.45%, and Jinbo Biological at 261.00, down 3.45% [1] Group 2 - The net outflow of main funds in the medical beauty sector was 41.23 million yuan, while retail investors saw a net inflow of 57.45 million yuan [1] - Specific stock fund flows indicated that *ST Meigu had a net inflow of 0.75%, while Huaxi Biological and Aimeike experienced net outflows of 8.64% and 6.24%, respectively [2]

Group 1 - The "Specialized, Refined, Unique, and Innovative" strategy closely aligns with the positioning of the Beijing Stock Exchange (BSE), focusing on cultivating specialized small and medium-sized enterprises (SMEs) to address critical issues in the industrial sector [3][8][10] - As of November 2024, over 140,000 specialized SMEs and 14,600 "Little Giant" enterprises have been cultivated in China, indicating a robust ecosystem for innovation and industrial upgrading [3][8] - The BSE's "Little Giants" account for over 50% of its total market capitalization, showcasing a strong foundation for the newly launched Specialized, Refined, Unique Index [3][27] Group 2 - The BSE Specialized, Refined, Unique Index was officially launched in June 2025, selecting the top 50 securities based on market capitalization from eligible "Little Giants," reflecting both scarcity and growth potential [3][27][38] - The index's top 15 constituent stocks account for 56% of its total weight, primarily concentrated in high-end manufacturing, new materials, and biomedicine sectors, with an average growth rate of approximately 57% since 2025 [3][41][40] - The index's methodology emphasizes liquidity and market capitalization, with adjustments made biannually to ensure it remains representative of the underlying market [3][33] Group 3 - The BSE's Specialized, Refined, Unique Index demonstrates superior growth characteristics compared to the BSE 50, with expectations for the first batch of index funds to reach several billion yuan in scale [3][40][38] - By 2027, the total scale of index funds linked to the BSE Specialized, Refined, Unique Index is projected to exceed 15 billion yuan, complementing the dual investment styles of "mainstream stability + innovative high growth" [3][40][38] - The index's performance has outpaced broader indices, indicating its potential as a differentiated investment benchmark for various investor preferences [3][36][38]